Last reviewed · How we verify
14-day antibiotic therapy
At a glance
| Generic name | 14-day antibiotic therapy |
|---|---|
| Also known as | Experimental arm |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) (PHASE2)
- VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Assessment of Masseter Muscle With Ultrasonography (NA)
- Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14-day antibiotic therapy CI brief — competitive landscape report
- 14-day antibiotic therapy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI